TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32540858
Drug: Tislelizumab 5
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 5 mg/kg every 3 weeks (Phase IB)
Study: 32540858
Drug: Tislelizumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab (all doses)
Study: 32541292
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine 1.3% (266 mg, 20 mL) and bupivacaine hydrochloride 0.25% (52 mg, 20 mL)
Study: 32542466
Drug: Darifenacin 15
Normalized name: darifenacin 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darifenacin 15 mg daily for 8 weeks
Study: 32542468
Drug: Flortaucipir PET
Normalized name: Flortaucipir
DrugBank: Flortaucipir (DB15033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flortaucipir PET (injection of ~370 mBq flortaucipir, 20-min PET scan starting 80 min post-injection)
Study: 32542577
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy initiated prior to sampling
Study: 32542577
Drug: No prior
Approvals — FDA: no, EMA: no, PMDA: no
Description: No prior antibiotic exposure
Study: 32542873
Drug: Current use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current use of antidepressants
Study: 32542873
Drug: Imipramine-type antidepressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine-type antidepressants
Study: 32542873
Drug: Other or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other or mixed antidepressants
Study: 32544297
Drug: N8-GP prophylaxis
Normalized name: N8-GP
DrugBank: Turoctocog alfa pegol (DB14738)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: N8-GP prophylaxis 75 IU/kg once weekly (Q7D)
Study: 32544297
Drug: N8-GP (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: N8-GP (all treatment arms)
Study: 32545856
Drug: ILTHPI (Intraluminal
Approvals — FDA: no, EMA: no, PMDA: no
Description: ILTHPI (Intraluminal Therapy for H. pylori Infection)
Study: 32546071
Drug: Blinatumomab (9-28-112
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab (9-28-112 μg/day) in a 70-day cycle 1 and an optional 28-day cycle 2
Study: 32546071
Drug: Blinatumomab (9-28-112
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blinatumomab (9-28-112 μg/day)
Study: 32546636
Drug: Incomplete aneurysm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incomplete aneurysm occlusion after initial treatment
Study: 32546636
Drug: Complete aneurysm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete aneurysm occlusion after initial treatment
Study: 32547188
Drug: Nanosomal docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nanosomal docetaxel lipid suspension (NDLS) chemotherapy (75-100 mg/m2)
Study: 32547188
Drug: Nanosomal docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nanosomal docetaxel lipid suspension (NDLS) chemotherapy
Study: 32547496
Drug: Preparation protocols
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation protocols
Study: 32550738
Drug: Analgesic (Lidocaine
Normalized name: Workvie Roll On Analgesic (lidocaine HCl 4 % / menthol 1 % ) Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic (Lidocaine hydrochloride 40 mg plus adrenaline 0.025 mg) with tenaculum replacement
Study: 32550738
Drug: Analgesic (Lidocaine
Normalized name: Workvie Roll On Analgesic (lidocaine HCl 4 % / menthol 1 % ) Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic (Lidocaine hydrochloride 40 mg plus adrenaline 0.025 mg) without tenaculum replacement
Study: 32550738
Drug: No analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No analgesic with tenaculum replacement
Study: 32550738
Drug: No analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No analgesic without tenaculum replacement
Study: 32551439
Drug: Cap-assisted endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cap-assisted endoscopic sclerotherapy with long injection needle
Study: 32551439
Drug: Cap-assisted endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cap-assisted endoscopic sclerotherapy with short injection needle
Study: 32551797
Drug: Okada Purifying
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Okada Purifying Therapy
Study: 32552266
Drug: Canakinumab 4
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab 4 mg/kg every 4 weeks for ≤48 weeks
Study: 32552278
Drug: Lack of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lack of health care provider HPV vaccine recommendation
Study: 32552278
Drug: Perceived lack
Normalized name: allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perceived lack of insurance coverage for the HPV vaccine
Study: 32552299
Drug: Doll therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doll therapy
Study: 34051177
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks for up to 24 months
Study: 32553149
Drug: Ozanimod 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod 1.0 mg oral capsule daily for 12 weeks (after 7-day dose escalation)
Study: 32554315
Drug: nab-paclitaxel monotherapy
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel monotherapy (240 mg/m)
Study: 32554609
Drug: E7046 (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7046 (125 mg)
Study: 32554609
Drug: E7046 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7046 (250 mg)
Study: 32554609
Drug: E7046 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7046 (500 mg)
Study: 32554609
Drug: E7046 (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7046 (750 mg)
Study: 32554609
Drug: E7046 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7046 (all doses)
Study: 32554740
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) using a limited sampling strategy (t=0 and t=5 hours)
Study: 38267496
Drug: Complement inhibitors
Normalized name: Complement inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complement inhibitors
Study: 32555070
Drug: Mindful movement
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindful movement treatment (8-week program, 2 classes per week for 60 minutes)
Study: 32555070
Drug: Mindful movement
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindful movement treatment
Study: 32555630
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg (6-9 injections)
Study: 32555630
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg (2-5 injections)
Study: 32555630
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg (1 injection)
Study: 32555630
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg (baseline VA <23 letters)
Study: 32556281
Drug: IV pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV pembrolizumab 10 mg/kg every 2 weeks for up to 2 years or until confirmed progression or unacceptable toxicity
Study: 32556682
Drug: High-dose stereotactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose stereotactic body radiation therapy (SBRT)
Study: 32556731
Drug: Cytoreduction, gastrectomy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreduction, gastrectomy, and HIPEC with 30 mg mitomycin C and 200 mg cisplatin
Study: 32556819
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy during EGD
Study: 32556819
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy during colonoscopy
Study: 32556819
Drug: No antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antithrombotic therapy during EGD
Study: 32556819
Drug: No antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antithrombotic therapy during colonoscopy
Study: 32557168
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injections (2.0 mg) administered using a fixed dosing regimen during the first year and a treat-and-extend treatment regimen during the second year.
Study: 32557382
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg weekly for up to 148 weeks
Study: 32557394
Drug: Tiotropium/Olodaterol fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium/Olodaterol fixed-dose combination (FDC) administered for 6 weeks
Study: 32557394
Drug: Tiotropium/Olodaterol fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium/Olodaterol fixed-dose combination (FDC)
Study: 32557834
Drug: Immunomodulatory treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory treatment
Study: 32557976
Drug: Matched targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched targeted agents for patients with druggable alterations
Study: 32558402
Drug: Open-label ganaxolone
Normalized name: ganaxolone
DrugBank: Ganaxolone (DB05087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label ganaxolone (225 mg twice daily, increased to 450 mg twice daily if tolerated) administered for 8 weeks
Study: 32558407
Drug: Escitalopram monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram monotherapy (10-20 mg daily for 8 weeks)
Study: 32558407
Drug: Aripiprazole augmentation
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole augmentation (2-10 mg daily for 8 weeks)
Study: 32558897
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with irradiated, CpG-activated tumor cells followed by reinfusion of vaccine-primed lymphocytes after ASCT
Study: 32559194
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of omics and clinical variables
Study: 32561087
Drug: Preoperative portal
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative portal embolization (PVE) plus administration of CD133 + cells mobilized from peripheral blood with G-CSF
Study: 32561664
Drug: Tislelizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab (200 mg i.v. Q3W) plus chemotherapy (cisplatin and fluorouracil for ESCC; oxaliplatin and capecitabine for G/GEJ)
Study: 32562609
Drug: EUS assessment
Normalized name: chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EUS assessment and endoscopic pancreatic function tests (ePFTs) with intravenous secretin 0.2 μg/kg
Study: 32563721
Drug: First anti-TNF
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: First anti-TNF therapy
Study: 32563721
Drug: Non-biologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-biologic therapy augmentation
Study: 32563721
Drug: Anti-TNF discontinuation
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF discontinuation
Study: 32564277
Drug: Epacadostat 25
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat 25 mg or 100 mg BID
Study: 32564277
Drug: Epacadostat 100
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat 100 mg BID with pembrolizumab 200 mg every 3 weeks
Study: 32564277
Drug: Epacadostat 25
Normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epacadostat 25 mg BID with pembrolizumab 200 mg every 3 weeks
Study: 32564277
Drug: Overall treatment-related
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment-related adverse events
Study: 32564301
Drug: Vixotrigine 150
Normalized name: Vixotrigine
DrugBank: Vixotrigine (DB11706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vixotrigine 150 mg three times daily for 6 days and once on day 7
Study: 32565475
Drug: Dialectical Behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialectical Behaviour Therapy (DBT) skill-infused college course, consisting of 15 weekly 2.5-hour lessons, weekly homework assignments, and a final examination.
Study: 32567415
Drug: Dehydrated human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dehydrated human amniotic membrane allograft (DAMA) with comprehensive care, applied weekly for 4 months
Study: 32567817
Drug: Osimertinib (80-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib (80-mg oral dose) in patients with severe renal impairment (SRI)
Study: 32567817
Drug: Osimertinib (80-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib (80-mg oral dose) in patients with normal renal function (NRF)
Study: 32568632
Drug: Biochemical nonadherence
Normalized name: PAD,NONADHERENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biochemical nonadherence to tamoxifen (serum level < 60 ng/mL)
Study: 32568632
Drug: Self-reported adherence
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported adherence to tamoxifen therapy
Study: 33722961
Drug: Neuroform Atlas
Normalized name: LACTIC ACID 0.58 g in 100 g TOPICAL LIQUID [Atlas Prep Activator]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroform Atlas Stent System with adjunctive coiling
Study: 32568958
Drug: Intravitreal and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal and sub-Tenon's injections of bone marrow-derived stem cells
Study: 32571613
Drug: High-normal inflammation
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-normal inflammation marker concentrations (hsCRP >0.57-9.98 mg/L, mid/upper tertile)
Study: 32572470
Drug: DENV-1-LVHC strain
Normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DENV-1-LVHC strain 45AZ5 (low-dose group: 0.5 mL of 6.5 × 103 PFU/mL)
Study: 32572470
Drug: DENV-1-LVHC strain
Normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DENV-1-LVHC strain 45AZ5 (mid-dose group: 0.5 mL of 6.5 × 104 PFU/mL)
Study: 32572470
Drug: DENV-1-LVHC strain
Normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DENV-1-LVHC strain 45AZ5 (both doses)
Study: 32572849
Drug: ePIPAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ePIPAC with oxaliplatin (92 mg/m2)
Study: 32574101
Drug: Seven-valent pneumococcal
Normalized name: Sevenfact
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seven-valent pneumococcal conjugate vaccine (PCV7)
Study: 32574101
Drug: Pneumococcal non-typeable
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal non-typeable vaccine
Study: 32575130
Drug: G-POEM (Gastric
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-POEM (Gastric Peroral Endoscopic Myotomy)
Study: 32576633
Drug: Clinical score
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical score (0 to 12 points) based on 6 variables: seizure(s) at presentation, known thrombophilia, oral contraception, duration of symptoms >6 days, worst headache ever, focal neurologic deficit at presentation.
Study: 32576633
Drug: D-dimers >675
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimers >675 μg/L (best cutoff)
Study: 32576633
Drug: D-dimers >500
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimers >500 μg/L
Study: 32576633
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clinical score and D-dimers >500 μg/L
Study: 32578220
Drug: IVF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVF therapy
Study: 32578441
Drug: RIPK1 kinase
Normalized name: Kinase (enzyme-activating), uro-urokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIPK1 kinase inhibitor (Nec-1)
Study: 32578964
Drug: Sequential bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sequential bortezomib (BTZ) 1.3 mg/m² intravenously + temozolomide (TMZ) therapy
Study: 32580249
Drug: Subsequent surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent surgical and nonsurgical therapies after primary treatment failure
Study: 32580249
Drug: Vinblastine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine monotherapy
Study: 32580249
Drug: First-line adjuvant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line adjuvant treatment
Study: 32580597
Drug: Chimeric antigen
Normalized name: Chimeric antigen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric antigen receptor-modified T cells
Study: 32580757
Drug: Hyperuricemia (SUA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperuricemia (SUA > 7 mg/dL in males and > 6 mg/dL in females)
Study: 32580757
Drug: Normouricemia (SUA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normouricemia (SUA ≤ 7 mg/dL in males and ≤ 6 mg/dL in females)
Study: 32580982
Drug: Zero Childhood
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zero Childhood Cancer Personalised Medicine Program
Study: 32580988
Drug: Septic cardiomyopathy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Septic cardiomyopathy assessment and comprehensive cardiovascular and molecular deep phenotyping including echocardiographic and electrocardiographic assessment, heart rate variability, body composition, mitochondrial oxygen metabolism, macrocirculation and microcirculation, endothelial barrier function, routine immunological, haematological and biochemical tests, serum metabolome and lipidome analyses, microbiome and epigenetic modifications of immune cells.
Study: 32580987
Drug: Antibiotic exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic exposure in the first year of life
Study: 32580987
Drug: Disruption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disruption of the infant oral and intestinal microbiome
Study: 32580987
Drug: Compositional overlap
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Compositional overlap between maternal intestinal microbiome, breast milk microbiome, and infant oral and intestinal microbiome
Study: 32581767
Drug: EAHE (Erinacine
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAHE (Erinacine A-Enriched) mycelia capsules, 5 mg/g, three capsules per day for 49 weeks
Study: 32581767
Drug: Placebo capsules,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules, identical in appearance to EAHE capsules, for 49 weeks
Study: 32581961
Drug: Rhythmic Reading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhythmic Reading Training (RRT) administered for 13 hours over 9 days
Study: 32581961
Drug: Visual Hemisphere-Specific
Normalized name: Fluzone 2025 Southern Hemisphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visual Hemisphere-Specific Stimulation (VHSS) + Action Video Game Training (AVG) administered for 13 hours over 9 days
Study: 32582547
Drug: P10s-PADRE vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P10s-PADRE vaccine
Study: 32583052
Drug: Alemtuzumab (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alemtuzumab (12 mg/day; baseline: 5 days; 12 months later: 3 days)
Study: 32583749
Drug: Drug-Coated Balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Coated Balloon Angioplasty
Study: 32584051
Drug: Intravenous alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alcohol self-administration (ivASA)
Study: 32586767
Drug: Atezolizumab 15
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab 15 mg/kg or 1200 mg intravenously every 3 weeks for 16 cycles or until loss of clinical benefit
Study: 32586937
Drug: Mogamulizumab 1
Normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mogamulizumab 1 mg/kg plus Durvalumab 10 mg/kg
Study: 32586937
Drug: Mogamulizumab 1
Normalized name: mogamulizumab
DrugBank: Mogamulizumab (DB12498)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mogamulizumab 1 mg/kg plus Tremelimumab 10 mg/kg
Study: 32586937
Drug: Mogamulizumab in
Normalized name: mogamulizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mogamulizumab in combination with Durvalumab or Tremelimumab
Study: 32588218
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (high intake of parenteral fluids)
Study: 32588218
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (low intake of parenteral fluids)
Study: 32589310
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 30 mg/day for 3 weeks, tapered off over 12 weeks
Study: 32589738
Drug: Nevanimibe (ATR-101)
Normalized name: Nevanimibe
DrugBank: Nevanimibe (DB16254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevanimibe (ATR-101) at doses of 125, 250, 500, 750, 1000 mg twice daily for 2 weeks followed by a 2-week placebo washout.
Study: 32590747
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg daily on days 1 to 21 of a 28-day cycle
Study: 32591978
Drug: Peficitinib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peficitinib (100 mg) administered twice daily from Day 3 to Day 9, coadministered with methotrexate on Day 8
Study: 32591978
Drug: Methotrexate (15-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (15-25 mg)